1. Home
  2. BHST vs PROK Comparison

BHST vs PROK Comparison

Compare BHST & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BHST
  • PROK
  • Stock Information
  • Founded
  • BHST 2007
  • PROK 2015
  • Country
  • BHST Canada
  • PROK United States
  • Employees
  • BHST N/A
  • PROK N/A
  • Industry
  • BHST
  • PROK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BHST
  • PROK Health Care
  • Exchange
  • BHST Nasdaq
  • PROK Nasdaq
  • Market Cap
  • BHST 106.0M
  • PROK 85.5M
  • IPO Year
  • BHST N/A
  • PROK N/A
  • Fundamental
  • Price
  • BHST N/A
  • PROK $0.64
  • Analyst Decision
  • BHST Strong Buy
  • PROK Hold
  • Analyst Count
  • BHST 2
  • PROK 3
  • Target Price
  • BHST $13.00
  • PROK $3.50
  • AVG Volume (30 Days)
  • BHST 8.9K
  • PROK 1.7M
  • Earning Date
  • BHST 08-15-2025
  • PROK 08-08-2025
  • Dividend Yield
  • BHST N/A
  • PROK N/A
  • EPS Growth
  • BHST N/A
  • PROK N/A
  • EPS
  • BHST N/A
  • PROK N/A
  • Revenue
  • BHST $27,704,000.00
  • PROK $306,000.00
  • Revenue This Year
  • BHST $116.40
  • PROK $54.34
  • Revenue Next Year
  • BHST $55.91
  • PROK N/A
  • P/E Ratio
  • BHST N/A
  • PROK N/A
  • Revenue Growth
  • BHST 74.76
  • PROK N/A
  • 52 Week Low
  • BHST $4.66
  • PROK $0.46
  • 52 Week High
  • BHST $7.86
  • PROK $2.59
  • Technical
  • Relative Strength Index (RSI)
  • BHST N/A
  • PROK 43.63
  • Support Level
  • BHST N/A
  • PROK $0.54
  • Resistance Level
  • BHST N/A
  • PROK $0.90
  • Average True Range (ATR)
  • BHST 0.00
  • PROK 0.13
  • MACD
  • BHST 0.00
  • PROK -0.02
  • Stochastic Oscillator
  • BHST 0.00
  • PROK 20.25

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: